Market Closed -
Other stock markets
|
After market 01:29:56 am | |||
0.879 EUR | -1.79% | 0.886 | +0.80% |
07:00am | Pharming Group N.V. Provides Revenue Guidance for 2024 | CI |
07:00am | Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.74% | 650M | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- Pharming Group Plans to Develop Leniolisib for Additional Primary Immunodeficiencies Following Engagement With FDA